Applicants: Marc Feldmann and Ravinder N. Maini

Serial No.: 09/754,004 Filed: January 3, 2001

Page 3

Please amend the subject application as follows:

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

- 1. (Currently Amended) A method for treating or preventing psoriatic arthritis an inflammatory discase an individual in need thereof comprising co-administering methotrexate and a TNFa antagonist to said individual, in therapeutically effective amounts.
- (Currently Amended) A method of Claim 1 wherein said TNFα antagonist and methotrexate are administered in a series of doses separated by intervals of days or weeks cimultaneously.

3.-5. (Canceled)

6. (Original) A method of Claim 1 wherein said TNF α antagonist prevents or inhibits TNF α synthesis or TNF α release.

7.-10. (Canceled)

11. (Currently Amended) A method of Claim $\underline{1}$ 5 wherein said TNF α antagonist is an anti-TNF α antibody or antigen-binding fragment thereof.

Applicants: Marc Feldmann and Ravinder N. Maini

Serial No.: 09/754,004 Filed: January 3, 2001

Page 4

- 12. (Original) A method of Claim 11 wherein said antiTNFα antibody or antigen-binding fragment is a chimeric antibody or chimeric fragment, wherein said chimeric antibody or chimeric fragment comprises a non-human variable region specific for TNFα or an antigen-binding portion thereof and a human constant region.
- 13. (Original) A method of Claim 12 wherein said chimeric antibody binds to one or more epitopes included in amino acid residues set forth in SEQ ID NO:1 or SEO ID NO:2.
- 14. (Original) A method of Claim 13 wherein said chimeric antibody competitively inhibits binding of TNFα to monoclonal antibody cA2.
- 15. (Original) A method of Claim 13 wherein said chimeric antibody is monoclonal antibody cA2.
- 16. (Original) A method of Claim 11 wherein said anti-TNF α antibody is a humanized antibody or antigen-binding fragment thereof.
- 17. (Original) A method of Claim 16 wherein said humanized antibody binds to one or more epitopes included in amino acid residues set forth in SEQ ID NO:1 or SEQ ID NO:2.

18.-38. (Canceled)